AAPG

Ascentage Pharma Group International (HKEX:6855) is a clinical-stage biotechnology company founded in 2009 and headquartered in Suzhou, China. The company focuses on developing innovative therapies for cancer treatment, chronic hepatitis B virus infections, and age-related diseases, primarily serving the Chinese mainland market. As a relatively young biotech firm that went public in January 2025, Ascentage operates in the highly specialized field of oncology drug development, with a particular emphasis on targeting specific protein interactions that can restore normal cell death processes in cancer cells.